Greenwich Biosciences, Inc.

9 articles with Greenwich Biosciences, Inc.

• Greenwich Biosciences to Present Analysis of Three Clinical Studies of Nabiximols for People with Multiple Sclerosis Related Spasticity at the American Academy of Physical Medicine and Rehabilitation (AAPM&R) Annual Assembly

  11/13/2020

  Greenwich Biosciences, U.S. subsidiary of GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, will present data from an analysis of three Phase 3 clinical trials of nabiximols in spasticity among persons with multiple sclerosis (MS) at the American Academy of Physical Medicine and Rehabilitation (AAPM&R) Virtual Annual Assembly

• 

  Beyond COVID-19: Biotech Beach Companies Reinvigorate Small Molecules, Cannabinoids and More

  4/15/2020

  The COVID-19 battle dominates the news, but it doesn’t constitute all the news. Here’s what several Southern California Biotech Beach companies are doing that you might have missed.

• GW Pharmaceuticals to Present at Upcoming Investor Conferences in December 2019

  11/22/2019

  GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc., the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that Justin Gover, GW’s Chief Executive Officer, will present at two upcoming conferences:.

• GW Pharmaceuticals to Present at Upcoming Investor Conferences - Oct. 31, 2019

  10/31/2019

  GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc., the world leader in the science, development, and commercialization of cannabinoid prescription medicines, announced that Stephen Schultz, GW’s Vice President of Investor Relations, will present at two upcoming conferences:.

• GW Pharmaceuticals Reports Positive Phase 3 Pivotal Trial Results for EPIDIOLEX® (cannabidiol) Oral Solution in Patients with Seizures Associated With Tuberous Sclerosis Complex

  5/6/2019

  GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced positive top-line results of a randomized, double-blind, placebo-controlled Phase 3 clinical trial of EPIDIOLEX

• 

  First Marijuana-Based Medicine for Epilepsy Now Available in the U.S.

  11/1/2018

  GW Pharmaceuticals, with offices in London, UK and Carlsbad, Calif., announced that its Epidiolex (cannabidiol) for seizures associated with Lennox-Gastaut syndrome (LGS) or Draven syndrome is now available in the United States.
• 

  Zogenix Still Chasing GW Pharma, but Epilepsy Drug Looks Good in 2nd Phase III Trial

  7/12/2018

  Zogenix announced positive top-line data from its second confirmatory Phase III clinical trial of ZX008 (low-dose fenfluramine hydrochloride) for children and young adults with Dravet syndrome.
• 

  Cannabis-Based Drug Developers Are Hopeful as FDA Approves First Marijuana-based Seizure Treatment

  6/26/2018

  In a first of its kind ruling, the U.S. Food and Drug Administration approved GW Pharmaceuticals’ Epidiolex, a cannabis-based treatment for seizures associated with two rare forms of epilepsy, Lennox-Gastaut syndrome (LGS) and Dravet syndrome.

• GW Pharmaceuticals and Its U.S. Subsidiary Greenwich Biosciences Announce Publication of Landmark Epidiolex (Cannabidiol) Study in The Lancet

  1/25/2018

  Treatment with Epidiolex was generally well tolerated, with a safety profile consistent with prior reported experience.